Tuesday, November 17, 2026
Judith Perera
- Considerable progress in being made in the development of vaccines against 10 major killer diseases, says the World Health Organisation (WHO), citing the powerful effect of the drive for profit in the developed world’s drug industries.
Western drug company researchers chasing the ready market in the industrialised countries, are looking at drugs with a wider reach — even if they may have western tourists and soldiers in mind rather than locals in mind when confronting disease.
But as the WHO notes in its latest report on the State of the World’s Vaccines and Immunisation, the sheer scale of private sector reaserach is throwing up some interesting products almost by accident.
“Ironically,” noted the report, “a vaccine against pneumococcal pneumonia and meningitis — which kills over a million children a year in developing countries — was developed largely to prevent the incidence of inner ear infections among children in the United States.”
But on the other hand some manufacturers have stopped vaccine research vital to developing countries — into HIV for example — because the need is no longer so great in the industrialised world.
The 10 vaccines under development which WHO considers most vital for developing countries are those for pneumococcal disease, meningoccocal meningitis, respiratory syncytial virus (RSV), rotavirus, shigella (dysentery), enterotoxigenic Escherichia coli (ETEC), HIV/AIDS, malaria, schistosomiasis, and dengue.
Between them pneumonia, diarrhoea, malaria, measles and malnutrition account for 75 per cent of all deaths in children under five.
Every year over a million children under five die of pneumonia in the developing world. A major problem is the development of resistance to antibiotics.
A recent study in Pakistan has shown that 95 per cent of all pneumococci studied had reduced sensitivity to at least one antibiotic and over 50 per cent were resistant to cotrimoxazole — the main drug used in these infections.
This makes development of a vaccine vital, although the large number (83) of different serotypes of the bacteria make this a difficult task. A new vaccine which protects against the 10 most common serotypes which also cause ear infections in the industrialised world, is now undergoing trials.
But it will be expensive to produce and new lines of research are being considered.
There are around 300,000 cases of meningococcal meningitis a year and 30,000 deaths worldwide, in addition to explosive epidemics which occur from time to time in the “meningitis belt” of Africa.
Vaccines were developed to combat epidemics among young U.S. military recruits but they are effective against only two of the three sub-types (A and C) and are useless for children under two. Development of a vaccine against subtype B is under way.
RSV kills around 900,000 people a year, mainly children. Little is known about the epidemiology of the disease and no satisfactory vaccine has yet been developed.
Rotavirus, which causes diarrhoea affects most children in the early years. In developing countries it accounts for 870,000 deaths a year in children under five. A vaccine developed in the US is now under going trials in Venezuela. The vaccine, given orally, could be easily incorporated into routine immunisation programmes in the developing world.
Dysentery kills some 600,000 people in the developing world each year and there is a growing problems if drug resistance. Several vaccines are now under development and work is under way on a combined vaccine which would also protect against ETEC, rotavirus, cholera and typhoid.
ETEC is the most common cause of diarrhoea in developing countries accounting for 400 million cases a year and up o 700,000 deaths in children under five. A promising vaccine is under development in Sweden and another in the United States.
The developing world accounts for 90 percent of the world’s 20 million HIV/AIDS cases with 11 million people affected in Africa so far — the worst affected region. However the biggest upsurge in cases is in south and southeast Asia.
The HIV virus poses a serious challenge to vaccine development because it directly attacks the immune system and also replicates and mutates very rapidly. Any vaccine is likely to be too expensive for most developing countries, and this is deterring research.
Malaria kills 1.5 million people a year in developing countries, mostly in Africa (90 per cent). As the disease is carried by parasites, vaccine development is only one of many different control strategies being developed.
Vaccine development is mainly publicly funded as the expense and complexity acts as a deterrent to manufacturers. Various different vaccines are under development which are targeted to different stages in the parasite’s life cycle.
But vaccines are seen only as part of a more general control programme.
The second most common tropical disease is schistosomiasis, a water-related parasite which affects up to 200 million people worldwide. It can lead to debilitating disease and eventual death. Several vaccines are under development and like those for malaria are seen as part of a wider control strategy.
Although dengue kills only 30,000 people a year, it affects over 50 million and is a serious drain on health services in endemic countries.
Several vaccines are under development with good prospects of eventually being adopted for general use.
While the burden of these diseases is being carried by the developing world, WHO points out that vaccine development is led by the needs of the industrialised countries.
“The initial cost of these newer vaccines is likely to be the biggest stumbling block in their immediate use in developing countries,” says WHO.
“In some cases the technology used could not be readily transferred to developing-country manufacturers. The immediate priority is to develop a vaccine that works and then find ways of reducing the cost.”